Neoadjuvant therapy in operable breast cancer: Application to triple negative breast cancer

Journal of Oncology

Volumn , Issue , 2013, Pages

  Ademuyiwa, Foluso O ^a   Ellis, Matthew J ^a   Ma, Cynthia X ^a  

^a USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CLAUDIN 3; CLAUDIN 4; CLAUDIN 7; CYCLOPHOSPHAMIDE; DASATINIB; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; EVEROLIMUS; GEMCITABINE; INIPARIB; IXABEPILONE; N (6,7 DIHYDRO 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL) 2,2 DIMETHYL N' (2,2,3,3,3 PENTAFLUOROPROPYL)PROPANEDIAMIDE; NAVELBINE; OLAPARIB; PACLITAXEL; SUNITINIB; VASCULOTROPIN;

ANDROGEN METABOLISM; ANTIGEN PRESENTATION; BASAL LIKE BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CELL MOTILITY; CHEMOSENSITIVITY; CLINICAL EXAMINATION; CLINICAL PRACTICE; CROSS LINKING; DISEASE FREE SURVIVAL; DNA DAMAGE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG EFFICACY; ECHOGRAPHY; EXCISION REPAIR; EXTRACELLULAR MATRIX; FOOD AND DRUG ADMINISTRATION; GENE AMPLIFICATION; GENE CONTROL; GENE EXPRESSION PROFILING; GENOMIC INSTABILITY; HOMOLOGOUS RECOMBINATION; HORMONAL THERAPY; HUMAN; LOCAL THERAPY; LOW RISK POPULATION; MAMMOGRAPHY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVARY CARCINOMA; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PREOPERATIVE PERIOD; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEIVER OPERATING CHARACTERISTIC; RECOMBINATION REPAIR; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; RESIDUAL VOLUME; RETROSPECTIVE STUDY; REVIEW; SAMPLE SIZE; SINGLE STRANDED DNA BREAK; STEROIDOGENESIS; SYSTEMIC THERAPY; TRIPLE NEGATIVE BREAST CANCER; TUMOR INVASION;

EID: 84883166969     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2013/219869     Document Type: Review

References (58)

1. Koplin L. M., O'Connell T. X., A new approach to the management of primary unresectable carcinoma of the breast: is radiation therapy necessary? American Journal of Clinical Oncology 1983 6 5 599 604 2-s2.0-0021057389
2. Fisher B., Bryant J., Wolmark N., Mamounas E., Brown A., Fisher E. R., Wickerham D. L., Begovic M., DeCillis A., Robidoux A., Margolese R. G., Cruz A. B. Jr., Hoehn J. L., Lees A. W., Dimitrov N. V., Bear H. D., Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. Journal of Clinical Oncology 1998 16 8 2672 2685 2-s2.0-0031926839
3. Ma C. X., Luo J., Ellis M. J., Molecular profiling of triple negative breast cancer. Breast Disease 2010 32 1-2 73 84 2-s2.0-80755129040 10.3233/BD-2010-0309
4. Sørlie T., Perou C. M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M. B., Van De Rijn M., Jeffrey S. S., Thorsen T., Quist H., Matese J. C., Brown P. O., Botstein D., Lønning P. E., Børresen-Dale A.-L., Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences of the United States of America 2001 98 19 10869 10874 2-s2.0-0035845511 10.1073/pnas.191367098
5. Kreike B., van Kouwenhove M., Horlings H., Weigelt B., Peterse H., Bartelink H., van de Vijver M. J., Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Research 2007 9 5, article R65 2-s2.0-36549004041 10.1186/bcr1771
6. Atchley D. P., Albarracin C. T., Lopez A., Valero V., Amos C. I., Gonzalez-Angulo A. M., Hortobagyi G. N., Arun B. K., Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. Journal of Clinical Oncology 2008 26 26 4282 4288 2-s2.0-52049086689 10.1200/JCO.2008.16.6231
7. Network TCGA, Comprehensive molecular portraits of human breast tumours. Nature 2012 490 61 70
8. Banerji S., Cibulskis K., Rangel-Escareno C., Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 2012 486 405 409
9. Ellis M. J., Ding L., Shen D., Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 2012 486 353 360
10. Shah S. P., Roth A., Goya R., The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012 486 395 399
11. Curtis C., Shah S. P., Chin S. F., The genomic and transcriptomic architecture of 2, 000 breast tumours reveals novel subgroups. Nature 2012 486 346 352
12. Stephens P. J., Tarpey P. S., Davies H., The landscape of cancer genes and mutational processes in breast cancer. Nature 2012 486 400 404
13. Ellis M. J., Perou C. M., The genomic landscape of breast cancer as a therapeutic roadmap. Cancer Discovery 2013 3 27 34
14. Lehmann B. D., Bauer J. A., Chen X., Sanders M. E., Chakravarthy A. B., Shyr Y., Pietenpol J. A., Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. The Journal of Clinical Investigation 2011 121 7 2750 2767 2-s2.0-79960015997 10.1172/JCI45014
15. Juul N., Szallasi Z., Eklund A. C., Li Q., Burrell R. A., Gerlinger M., Valero V., Andreopoulou E., Esteva F. J., Symmans W. F., Desmedt C., Haibe-Kains B., Sotiriou C., Pusztai L., Swanton C., Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. The Lancet Oncology 2010 11 4 358 365 2-s2.0-77950341123 10.1016/S1470-2045(10)70018-8
16. Bertucci F., Finetti P., Cervera N., Charafe-Jauffret E., Mamessier E., Adélaïde J., Debono S., Houvenaeghel G., Maraninchi D., Viens P., Charpin C., Jacquemier J., Birnbaum D., Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Research 2006 66 9 4636 4644 2-s2.0-33646390671 10.1158/0008-5472.CAN-06-0031
17. Doane A. S., Danso M., Lal P., Donaton M., Zhang L., Hudis C., Gerald W. L., An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 2006 25 28 3994 4008 2-s2.0-33745603978 10.1038/sj.onc.1209415
18. Ryan P. D., Tung N. M., Isakoff S. J., Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): safety and efficacy. Proceedings of the ASCO Annual Meeting 2009 Chicago, Ill, USA ASCO
19. Bear H. D., Tang G., Rastogi P., Geyer C. E. Jr., Robidoux A., Atkins J. N., Baez-Diaz L., Brufsky A. M., Mehta R. S., Fehrenbacher L., Young J. A., Senecal F. M., Gaur R., Margolese R. G., Adams P. T., Gross H. M., Costantino J. P., Swain S. M., Mamounas E. P., Wolmark N., Bevacizumab added to neoadjuvant chemotherapy for breast cancer. The New England Journal of Medicine 2012 366 4 310 320 2-s2.0-84856253589 10.1056/NEJMoa1111097
20. Huober J., von Minckwitz G., Denkert C., Tesch H., Weiss E., Zahm D. M., Belau A., Khandan F., Hauschild M., Thomssen C., Högel B., Darb-Esfahani S., Mehta K., Loibl S., Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Research and Treatment 2010 124 1 133 140 2-s2.0-77957710541 10.1007/s10549-010-1103-9
21. Alba E., Chacon J. I., Lluch A., A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study. Breast Cancer Research and Treatment 2012 136 487 493
22. Silver D. P., Richardson A. L., Eklund A. C., Wang Z. C., Szallasi Z., Li Q., Juul N., Leong C.-O., Calogrias D., Buraimoh A., Fatima A., Gelman R. S., Ryan P. D., Tung N. M., De Nicolo A., Ganesan S., Miron A., Colin C., Sgroi D. C., Ellisen L. W., Winer E. P., Garber J. E., Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. Journal of Clinical Oncology 2010 28 7 1145 1153 2-s2.0-77949908546 10.1200/JCO.2009.22.4725
23. Sirohi B., Arnedos M., Popat S., Ashley S., Nerurkar A., Walsh G., Johnston S., Smith I. E., Platinum-based chemotherapy in triple-negative breast cancer. Annals of Oncology 2008 19 11 1847 1852 2-s2.0-54949097426 10.1093/annonc/mdn395
24. Kern P., Kolberg H. C., Kalisch A., Pathologic response rate (pCR) and near-pathologic response rate (near-pCR) with docetaxel-carboplatin (TCarb) in early triple-negative breast cancer. Proceedings of the Breast Cancer Symposium 2011
25. Tiley S., Raab R. E., Bellin L. S., Results of the East Carolina Breast Center phase II trial of neoadjuvant metronomic chemotherapy in triple-negative breast cancer (NCT00542191). Proceedings of the ASCO Annual Meeting 2012 Chicago, Ill, USA ASCO
26. http://www.clinicaltrials.gov/
27. Llombart A., Lluch A., Villanueva C., SOLTI NeoPARP: a phase II, randomized study of two schedules of iniparib plus paclitaxel and paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer (TNBC). Proceedings of the ASCO Annual Meeting 2012 Chicago, Ill, USA ASCO
28. Gonzalez-Angulo A. M., Green M. C., Murray J. L., Open label, randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC, (T-FEC) versus the combination of paclitaxel and RAD001 followed by FEC, (TR-FEC) in women with triple receptor-negative breast cancer (TNBC). Proceedings of the ASCO Annual Meeting 2011 ASCO
29. Carey L. A., Dees E. C., Sawyer L., Gatti L., Moore D. T., Collichio F., Ollila D. W., Sartor C. I., Graham M. L., Perou C. M., The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clinical Cancer Research 2007 13 8 2329 2334 2-s2.0-33847063053 10.1158/1078-0432.CCR-06- 1109
30. Sikov W. M., Dizon D. S., Strenger R., Legare R. D., Theall K. P., Graves T. A., Gass J. S., Kennedy T. A., Fenton M. A., Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a brown university oncology group study. Journal of Clinical Oncology 2009 27 28 4693 4700 2-s2.0-70350464164 10.1200/JCO.2008.21.4163
31. Chen X. S., Nie X. Q., Chen C. M., Wu J. Y., Wu J., Lu J. S., Shao Z. M., Shen Z. Z., Shen K. W., Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer. Annals of Oncology 2010 21 5 961 967 2-s2.0-77953327187 10.1093/annonc/mdq041
32. Roy V., Pockaj B. A., Allred J. B., Apsey H., Northfelt D. W., Nikcevich D., Mattar B., Perez E. A., A phase II trial of docetaxel and carboplatin administered every 2 weeks as preoperative therapy for stage II or III breast cancer: NCCTG Study N0338. American Journal of Clinical Oncology 2012 10.1097/COC.0b013e318256f619
33. Chang H. R., Glaspy J., Allison M. A., Kass F. C., Elashoff R., Chung D. U., Gornbein J., Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment. Cancer 2010 116 18 4227 4237 2-s2.0-77957357280 10.1002/cncr.25309
34. Baselga J., Zambetti M., Llombart-Cussac A., Manikhas G., Kubista E., Steger G. G., Makhson A., Tjulandin S., Ludwig H., Verrill M., Ciruelos E., Egyhazi S., Xu L.-A., Zerba K. E., Lee H., Clark E., Galbraith S., Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. Journal of Clinical Oncology 2009 27 4 526 534 2-s2.0-59149087388 10.1200/JCO.2007.14.2646
35. Schneider B. P., Miller K. D., Angiogenesis of breast cancer. Journal of Clinical Oncology 2005 23 8 1782 1790 2-s2.0-15544391142 10.1200/JCO.2005.12.017
36. von Minckwitz G., Eidtmann H., Rezai M., Fasching P. A., Tesch H., Eggemann H., Schrader I., Kittel K., Hanusch C., Kreienberg R., Solbach C., Gerber B., Jackisch C., Kunz G., Blohmer J.-U., Huober J., Hauschild M., Fehm T., Müller B. M., Denkert C., Loibl S., Nekljudova V., Untch M., Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. The New England Journal of Medicine 2012 366 4 299 309 2-s2.0-84856291930 10.1056/NEJMoa1111065
37. Tutt A., Robson M., Garber J. E., Domchek S. M., Audeh M. W., Weitzel J. N., Friedlander M., Arun B., Loman N., Schmutzler R. K., Wardley A., Mitchell G., Earl H., Wickens M., Carmichael J., Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. The Lancet 2010 376 9737 235 244 2-s2.0-77955019276 10.1016/S0140-6736(10)60892-6
38. Gelmon K. A., Tischkowitz M., Mackay H., Swenerton K., Robidoux A., Tonkin K., Hirte H., Huntsman D., Clemons M., Gilks B., Yerushalmi R., Macpherson E., Carmichael J., Oza A., Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. The Lancet Oncology 2011 12 9 852 861 2-s2.0-80052389761 10.1016/S1470-2045(11) 70214-5
39. Fong P. C., Boss D. S., Yap T. A., Tutt A., Wu P., Mergui-Roelvink M., Mortimer P., Swaisland H., Lau A., O'Connor M. J., Ashworth A., Carmichael J., Kaye S. B., Schellens J. H. M., De Bono J. S., Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. The New England Journal of Medicine 2009 361 2 123 134 2-s2.0-67650471685 10.1056/NEJMoa0900212
40. Guarneri V., Broglio K., Kau S.-W., Cristofanilli M., Buzdar A. U., Valero V., Buchholz T., Meric F., Middleton L., Hortobagyi G. N., Gonzalez-Angulo A. M., Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. Journal of Clinical Oncology 2006 24 7 1037 1044 2-s2.0-33644973070 10.1200/JCO.2005.02.6914
41. Liedtke C., Mazouni C., Hess K. R., André F., Tordai A., Mejia J. A., Symmans W. F., Gonzalez-Angulo A. M., Hennessy B., Green M., Cristofanilli M., Hortobagyi G. N., Pusztai L., Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. Journal of Clinical Oncology 2008 26 8 1275 1281 2-s2.0-41649102048 10.1200/JCO.2007.14.4147
42. von Minckwitz G., Untch M., Blohmer J. U., Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. Journal of Clinical Oncology 2012 30 1796 1804
43. Sinn B. V., Darb-Esfahani S., Wirtz R. M., Faggad A., Weichert W., Buckendahl A.-C., Noske A., Müller B. M., Budczies J., Sehouli J., Braicu E. I., Dietel M., Denkert C., Vascular endothelial growth factor C mRNA expression is a prognostic factor in epithelial ovarian cancer as detected by kinetic RT-PCR in formalin-fixed paraffin-embedded tissue. Virchows Archiv 2009 455 6 461 467 2-s2.0-73449103846 10.1007/s00428-009-0851-6
44. Green M. C., Buzdar A. U., Smith T., Ibrahim N. K., Valero V., Rosales M. F., Cristofanilli M., Booser D. J., Pusztai L., Rivera E., Theriault R. L., Carter C., Frye D., Hunt K. K., Symmans W. F., Strom E. A., Sahin A. A., Sikov W., Hortobagyi G. N., Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. Journal of Clinical Oncology 2005 23 25 5983 5992 2-s2.0-24944542869 10.1200/JCO.2005.06.232
45. Baselga J., Bradbury I., Eidtmann H., Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. The Lancet 2012 379 633 640
46. Steger G. G., Galid A., Gnant M., Mlineritsch B., Lang A., Tausch C., Rudas M., Greil R., Wenzel C., Singer C. F., Haid A., Pöstlberger S., Samonigg H., Luschin-Ebengreuth G., Kwasny W., Klug E., Kubista E., Menzel C., Jakesz R., Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14. Journal of Clinical Oncology 2007 25 15 2012 2018 2-s2.0-34249934818 10.1200/JCO.2006.09.1777
47. Bear H. D., Anderson S., Brown A., Smith R., Mamounas E. P., Fisher B., Margolese R., Theoret H., Soran A., Lawrence Wickerham D., Wolmark N., The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. Journal of Clinical Oncology 2003 21 22 4165 4174 2-s2.0-0642347622 10.1200/JCO.2003.12.005
48. Sataloff D. M., Mason B. A., Prestipino A. J., Seinige U. L., Lieber C. P., Baloch Z., Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. Journal of the American College of Surgeons 1995 180 3 297 306 2-s2.0-0028941079
49. Mazouni C., Peintinger F., Wan-Kau S., Andre F., Gonzalez-Angulo A. M., Symmans W. F., Meric-Bernstam F., Valero V., Hortobagyi G. N., Pusztai L., Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. Journal of Clinical Oncology 2007 25 19 2650 2655 2-s2.0-34447577933 10.1200/JCO.2006.08.2271
50. Symmans W. F., Peintinger F., Hatzis C., Rajan R., Kuerer H., Valero V., Assad L., Poniecka A., Hennessy B., Green M., Buzdar A. U., Singletary S. E., Hortobagyi G. N., Pusztai L., Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. Journal of Clinical Oncology 2007 25 28 4414 4422 2-s2.0-35348824912 10.1200/JCO.2007.10.6823
51. Ogston K. N., Miller I. D., Payne S., Hutcheon A. W., Sarkar T. K., Smith I., Schofield A., Heys S. D., A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. The Breast 2003 12 5 320 327 2-s2.0-0142211270 10.1016/S0960-9776(03) 00106-1
52. Balko J. M., Wang K., Sanders M. E., Profiling of triple-negative breast cancers after neoadjuvant chemotherapy identifies targetable molecular alterations in the treatment-refractory residual disease. Proceedings of the San Antonio Breast Cancer Symposium 2013 San Antonio, Tex, USA S3 S6
53. von Minckwitz G., Blohmer J.-U., Raab G., Löhr A., Gerber B., Heinrich G., Eidtmann H., Kaufmann M., Hilfrich J., Jackisch C., Zuna I., Costa S. D., In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: The GEPARTRIO Pilot Study. Annals of Oncology 2005 16 1 56 63 2-s2.0-19944426993 10.1093/annonc/mdi001
54. Smith I. C., Heys S. D., Hutcheon A. W., Miller I. D., Payne S., Gilbert F. J., Ah-See A. K., Eremin O., Walker L. G., Sarkar T. K., Eggleton S. P., Ogston K. N., Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. Journal of Clinical Oncology 2002 20 6 1456 1466 2-s2.0-0037087562 10.1200/JCO.20.6.1456
55. Londero V., Bazzocchi M., Del Frate C., Puglisi F., Di Loreto C., Francescutti G., Zuiani C., Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy. European Radiology 2004 14 8 1371 1379 2-s2.0-3042514833
56. Chagpar A. B., Middleton L. P., Sahin A. A., Dempsey P., Buzdar A. U., Mirza A. N., Ames F. C., Babiera G. V., Feig B. W., Hunt K. K., Kuerer H. M., Meric-Bernstam F., Ross M. I., Singletary S. E., Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. Annals of Surgery 2006 243 2 257 264 2-s2.0-31844444246 10.1097/01.sla.0000197714.14318.6f
57. Groheux D., Hindié E., Giacchetti S., Delord M., Hamy A.-S., De Roquancourt A., Vercellino L., Berenger N., Marty M., Espié M., Triple-negative breast cancer: Early assessment with18F-FDG PET/CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathologic complete response and are at a high risk of early relapse. Journal of Nuclear Medicine 2012 53 2 249 254 2-s2.0-84856806192 10.2967/jnumed.111.094045
58. Mamounas E. P., Brown A., Anderson S., Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. Journal of Clinical Oncology 2005 23 2694 2702